The Sanford Guide to Antimicrobial Therapy 2019 Library Edition

The 49th edition of the leading clinical reference on treatment of infectious diseases and anti-infective drug information. Helpful in day-to-day practice and as a component of your organization's antimicrobial stewardship program, the Sanford Guide provides valuable guidance in the age of antibiotic resistance. Popular with physicians, pharmacists, physician assistants, nurse practitioners, and other clinicians, the Sanford Guide to Antimicrobial Therapy provides information that is convenient, concise, and reliable.

Available in print in pocket size, spiral bound and large library editions.

Coverage includes:

• Clinical syndromes
  
  • pathogens
  • bacterial
  • fungal
  • mycobacterial
  • parasitic
  • viral
• Anti-infective agents
  
  • dosing
    
    • pediatric adjustments
    • renal adjustments
  • adverse affects
  • activity
  • pharmacology
  • interactions
• Preventative therapy

What's new in 2019:

Table 1: osteomyelitis, mastitis, brain abscess, encephalitis, meningitis, otitis media, keratitis, gastroenteritis, urethritis, syphilis, pyelonephritis, vaginosis, endocarditis, prosthetic joint, UTIs, pneumonia (esp. GNB), pancreatitis, peritonitis, bites, burns, cellulitis, Lyme, febrile syndromes, sepsis, shock, botulism, IV lines/catheters, vascular
Table 2: resistant bacteria, including GNB
Table 3: duration of therapy
Table 4: organism coverage expanded, drugs added (new and old)
Table 5B: updated treatment options for GNB
Table 6: updated recommendations for management of MRSA
Table 8: pregnancy risk for new drugs
Table 9: PK & interactions data for new drugs added
Table 10: dosing updated and recent drugs added, e.g., plazomicin, eravacycline, omadacycline, temocillin, secnidazole
Table 11: cryptococcosis
Table 12: latent TB, MAC, M. abscessus
Table 13: malaria, tafenoquine
Table 14A: hemorrhagic fevers, influenza
Table 14B: new HCV, CMV drugs
Table 14C: new ARV drugs & combinations, updated recommended ART regimens
Table 14F: updated HCV treatment regimens and recommendations
Table 15: post-exposure prophylaxis
Table 16: added peds dosing for additional antibacterials, ARVs, antivirals
Table 17: renal adjustments for new drugs added
Table 17C: updated obesity dose adjustments
Table 22: DDIs completely reworked to focus on effects and suggested management